← Leaderboards
Lbachir Benmohamed
University Of California-Irvine
$21,933,314
Attributed
$21,933,314
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,933,314 · 12
By mechanism
R01$20,185,396 · 7
R21$1,055,938 · 3
R03$456,000 · 1
R41$235,980 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California-Irvine
Same institution · by research overlap
- Kevin T Beier$7,045,503
- Gregory Corder$7,054,744
- Xiangmin Xu$44,991,808
- Marcelo Andres Wood$22,715,150
- Christie D Fowler$8,621,482
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteInfectionPreventSimplexvirusVaccinesCd8b1 GeneLeadVirusImmunityT-Lymphocyte EpitopesBaseImmunizationInnovationRecurrenceCd8-Positive T-LymphocytesPublishingUnited StatesAfferent NeuronsProteinsCellsEpitopesBlindnessViralChemokine
Grant awards (53)
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine$409,999
R01 · FY2025 · EY · contact PI
Developing a Multi-epitope Pan-Coronavirus Vaccine$727,670
R01 · FY2024 · AI · contact PI
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes$612,901
R01 · FY2024 · AI · contact PI
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine$409,999
R01 · FY2024 · EY · contact PI
Developing a Multi-epitope Pan-Coronavirus Vaccine$742,241
R01 · FY2023 · AI · contact PI
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes$612,901
R01 · FY2023 · AI · contact PI
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine$409,999
R01 · FY2023 · EY · contact PI
Developing a Multi-epitope Pan-Coronavirus Vaccine$756,900
R01 · FY2022 · AI · contact PI
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes$612,901
R01 · FY2022 · AI · contact PI
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes$599,734
R01 · FY2022 · AI · contact PI
Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine$409,999
R01 · FY2022 · EY · contact PI
Developing a Multi-epitope Pan-Coronavirus Vaccine$717,976
R01 · FY2021 · AI · contact PI
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes$684,899
R01 · FY2021 · AI · contact PI
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes$603,265
R01 · FY2021 · AI · contact PI
Developing a Multi-epitope Pan-Coronavirus Vaccine$745,410
R01 · FY2020 · AI · contact PI
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes$697,459
R01 · FY2020 · AI · contact PI
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes$602,162
R01 · FY2020 · AI · contact PI
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-Pathogenesis$231,750
R21 · FY2020 · AI · contact PI
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLES$210,375
R21 · FY2020 · AI · contact PI
Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes$613,293
R01 · FY2019 · AI · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$463,500
R01 · FY2019 · EY · contact PI
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease$375,018
R01 · FY2019 · EY · contact PI
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-Pathogenesis$231,750
R21 · FY2019 · AI · contact PI
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLES$188,938
R21 · FY2019 · AI · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$463,500
R01 · FY2018 · EY · contact PI
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease$375,018
R01 · FY2018 · EY · contact PI
A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINE$235,980
R41 · FY2018 · AI · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$463,500
R01 · FY2017 · EY · contact PI
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease$382,743
R01 · FY2017 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$463,500
R01 · FY2016 · EY · contact PI
Mechanisms of CD8+ T Cell Dynamics in Recurrent Ocular Herpetic Disease$388,073
R01 · FY2016 · EY · contact PI
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe$386,250
R01 · FY2016 · EY · contact PI
LAT-HVEM Interactions Effect HSV-1 Latency/Reactivation$193,125
R21 · FY2016 · AI · contact PI
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe$378,525
R01 · FY2015 · EY · contact PI
Blockade of T-cell Co-Inhibitory Pathways & Immunotherapy to Prevent Ocular Herpe$386,250
R01 · FY2014 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptide$374,850
R01 · FY2014 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$359,856
R01 · FY2014 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptide$363,375
R01 · FY2013 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$348,840
R01 · FY2013 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptide$382,500
R01 · FY2012 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$367,200
R01 · FY2012 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$367,200
R01 · FY2011 · EY · contact PI
Ocular Mucsoal Immunity Induced by HSV-1 Lipopeptides$382,500
R01 · FY2010 · EY · contact PI
Therapeutic Ocular HSV Vaccine in HLA Transgenic Rabbits$191,250
R01 · FY2010 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides$296,164
R01 · FY2007 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides$297,833
R01 · FY2006 · EY · contact PI
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides$305,000
R01 · FY2005 · EY
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides$303,333
R01 · FY2004 · EY
Interaction of HSV-1 LAT Gene &Dendritic Cells Function$151,500
R03 · FY2004 · EY
Ocular Mucosal Immunity Induced by HSV-1 Lipopeptides$349,910
R01 · FY2003 · EY
Interaction of HSV-1 LAT Gene &Dendritic Cells Function$151,500
R03 · FY2003 · EY
Interaction of HSV-1 LAT Gene &Dendritic Cells Function$102,277
R03 · FY2002 · EY
Interaction of HSV-1 LAT Gene &Dendritic Cells Function$50,723
R03 · FY2002 · EY